(lp0
S'Maxim Analyst Comments on Cytori Therapeutics Inc Following Azaya Acquisition Smarter Analyst - Jan 19, 2017 Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc  with a price target of $6.00, after the drug developer announced the acquisitions of Azaya Therapeutics for its proprietary liposomal nanoparticle&nbsp;...Cytori Therapeutics stock surges 7.9% on agreement to buy assets from Azaya ... - MarketWatchCytori Therapeutics  to Acquire Assets from Privately Held Azaya ... - StreetInsider.com'
p1
aS'Cytori Therapeutics Inc  Stock Rating Upgraded by Zacks Investment Research Chaffey Breeze - Mar 14, 2017 Cytori Therapeutics logo Cytori Therapeutics Inc  was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued to clients and investors on Monday.Cytori Therapeutics Inc  has been upgraded to Hold in a statement ... - Breaking Finance News'
p2
aS"Maxim's Biotech Insights: Cytori Therapeutics Inc , StemCells Inc  Smarter Analyst - Mar 28, 2016 Recent developments in biotech stocks Cytori Therapeutics Inc  and StemCells Inc  attract analysts' attention as pipeline treatments inch toward the end of their final testing phases."
p3
aS'Stock Update : Cytori Therapeutics Inc Announces Increase of ... Smarter Analyst - Sep 19, 2016 Cytori Therapeutics Inc  announced that the Company and Biomedical Advanced Research and Development Authority , a division of the U.S.'
p4
aS'Quick Review on Trend Indicator Levels: Cytori Therapeutics Inc  Rives Journal - 15 hours ago Technical Traders may be interested in looking at the indicator levels on shares of Cytori Therapeutics Inc . The 14-day ADX for Cytori Therapeutics Inc  is currently 12.16. In general, an ADX value from 0-25 would signal an absent or ...'
p5
aS'Correcting The Facts On Cytori Therapeutics Seeking Alpha - Apr 14, 2015 On April 8th, 2015, TheStreet.com published an article by Adam Feuerstein on Cytori Therapeutics . The article was notable for its vindictiveness as it skewered the company for a Benzinga article that included an interview with Cytori CEO,&nbsp;...'
p6
aS'CYTORI THERAPEUTICS, INC.  Files An 8-K Entry into a Material ... Market Exclusive - Mar 3, 2017 Cytori Therapeutics, Inc.  is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy.The Cytori Therapeutics Inc  Price Target Increased to $10.00 by ... - DailyQuint'
p7
aS'Cytori Therapeutics Inc.: Cytori Completes Acquisition of Azaya Therapeutics ... The Wall Street Transcript - Feb 15, 2017 15, 2017  -- Cytori Therapeutics, Inc.  today announced it has completed its acquisition of assets of privately held Azaya Therapeutics, Inc., a leader in the research, development and manufacturing of nanoparticle&nbsp;...Cytori Therapeutics, Inc.  PT Raised to $10 at Maxim Group on Closure of ... - StreetInsider.com'
p8
aS'Stock Update : Cytori Therapeutics Inc Partner Kerastem Completes ... Smarter Analyst - Sep 26, 2016 Cytori Therapeutics Inc  announced that its licensee Kerastem Technologies, LLC, has completed enrollment of STYLE, a US phase II clinical trial investigating early stage female and male pattern hair loss.'
p9
aS"Cytori Therapeutics'  CEO Marc Hedrick on Q1 2016 Results - Earnings ... Seeking Alpha - May 11, 2016 Second, management feels that the combination of the forecasted spend and revenue may be sufficient to get the Company to the point of breakeven by 2018.Stock Update : Cytori Therapeutics Inc Granted Broad European ... - Smarter Analyst"
p10
a.